VKORC1 and venous thromboembolism: The genotype-guided dosing algorithm included clinical variables and genotyping for CYP2C9 and VKORC1 and the control-dosing algorithm included only clinical variables for the initiation of acenocoumarol or phenprocoumon treatment in patients with AF or venous thromboembolism.